Neluxicapone (INNTooltip International Nonproprietary Name) is a catechol O-methyltransferase (COMT) inhibitor which has not been marketed as of 2024.

[1][2][3] The drug is a nitrocatechol and is structurally related to other catechol COMT inhibitors like entacapone, tolcapone, and nebicapone.

[4][3] COMT inhibitors are used in conjunction with levodopa in the treatment of Parkinson's disease.

[3][1] Its INNTooltip International Nonproprietary Name was designated by the World Health Organization (WHO) in 2019.

This drug article relating to the nervous system is a stub.